1. Introduction {#sec1}
===============

Viral hemorrhagic fevers (VHF) are a group of systemic diseases caused by certain viruses, such as Ebola, Lassa, Dengue, and Crimean-Congo hemorrhagic fever viruses. Patients with VHF show the common cardinal symptoms, including fever, hemorrhages, and shock \[[@B1]\]. Data obtained over the past years indicate that these diseases are characterized by intense inflammatory responses with generalized signs of increased vascular permeability, severely impaired immune functions, diffuse vascular dysregulation, and coagulation abnormalities \[[@B2], [@B3]\]. VHF are generally prevalent in developing countries, which have posed a serious public health threat with high mortality, morbidity, and infectivity in recent years \[[@B4]\]. Currently, many large pharmaceutical companies are pursuing an effective antiviral therapy for VHF. Although the broad-spectra antiviral drug ribavirin is approved for treatment of several types of VHF, there remains a need for a safe and more effective medication to replace the antiviral drug \[[@B5]\].

Traditional Chinese Medicine (TCM) formulas consisting of complex mixtures of multiple plants play an outstanding role in the treatment of various acute infectious diseases because of the pharmacological and pharmacokinetic synergistic effects of the abundant bioactive ingredients \[[@B6]\]. A series of TCM prescriptions for hemorrhagic fever syndromes have been described in history \[[@B7], [@B8]\]. For example, XJDH is a famous TCM formula for treating hemorrhagic fever syndromes \[[@B9]\]. XJDH originally comes from "Prescriptions Worth A Thousand Gold" which is written by the "Medicinal King" Sun Simiao in the Tang Dynasty (around 700 AD) \[[@B10], [@B11]\]. The components of the formula include*Rhino horn* (substituted by*Buffalo Horn* now, Shui Niujiao in Chinese),*Rehmannia dried* rhizome (Sheng Dihuang in Chinese),*Paeonia lactiflora* Pall. (Shao Yao in Chinese), and*Paeonia suffruticosa* Andr. (Mu Danpi in Chinese). Actually, XJDH has been normally used for cooling the blood for hemostasis, stopping bleeding accompanied with fever, removing toxic substances, and treating the cases of high fever and sweating, spontaneous bleeding, hemoptysis, and nosebleeds \[[@B12], [@B13]\]. Although the therapeutic efficiency of XJDH in the treatment of VHF is attractive, several fundamental questions are still unclear. What are the potential active ingredients of XJDH? What are the underlying molecular mechanisms of action of the formula in the treatment of VHF? What are the precise targets of these medicines? Since the multiple components-multiple targets interaction model of TCM formulas, traditional experimental research methods show up the shortcomings of long-term investment.

Fortunately, as an emerging discipline, systems pharmacology provides a new way to solve the complex pharmacological problems \[[@B14]\]. Systems pharmacology integrates pharmacokinetic data (ADME/T characteristics of a drug) screening together with targets prediction, networks, and pathways analyses to explore the drug actions from molecular and cellular levels to tissue and organism levels. It also provides an analysis platform for decoding molecular mechanisms of TCM formulas. In our previous work, a series of systems pharmacology methods have been exploited to uncover the underlying mechanisms of action of TCM formulas for cardiovascular diseases, depression, and cancer \[[@B15]--[@B17]\].

The purpose of the present study is to investigate the underlying molecular mechanisms of XJDH in treating VHF based on systems pharmacology method. Firstly, four pharmacokinetic models, including oral bioavailability (OB), drug-likeness (DL), Caco-2 permeability, and drug half-life (HL), were employed to filter out the potential active ingredients with favorable ADME profiles from XJDH. Then, based on an integrated target prediction method which combined the biological and mathematical models, the corresponding targets of these active ingredients were identified. Finally, the network pharmacology and VHF-related signaling pathways analysis was carried out to systematically disclose the underlying interactions between drugs, target proteins, and pathways. The detailed flowchart of the systems pharmacology method is shown in [Figure 1](#fig1){ref-type="fig"}.

2. Materials and Methods {#sec2}
========================

2.1. Active Compounds Database {#sec2.1}
------------------------------

All chemicals of these four medicines in XJDH were manually collected from a wide-scale text mining and our in-house developed database: the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP, <http://lsp.nwsuaf.edu.cn/tcmsp.php>) \[[@B18]\]. In order to obtain the potential active compounds from these medicines, we applied a method incorporating OB, DL, Caco-2 permeability, and drug HL evaluation in this work.

### 2.1.1. OB Prediction {#sec2.1.1}

OB is defined as "the ratio of how many active components absorbed into the circulatory system to play a role at the site of action." OB is one of the vital pharmacokinetic profiles in active compounds screening processes. In this work, the OB screening was calculated by a robust in-house system, OBioavail1.1 \[[@B19]\], and components with OB ≥ 30% were selected as the candidate molecules for further study. The following two basic sections describe the design principles of the threshold: (1) information from the studied medicines is obtained as much as possible using the least number of compounds and (2) the established model can be elucidated within reason by the reported pharmacological data \[[@B6]\].

### 2.1.2. DL Prediction {#sec2.1.2}

DL generally means "molecule which holds functional groups and/or has physical properties consistent with the majority of known drugs" \[[@B21]\]. In this study, we performed a self-constructed model pre-DL (predicts drug-likeness) based on the molecular descriptors and Tanimoto coefficient \[[@B22]\]. The DL index of the compounds was calculated by Tanimoto coefficient defined as$$\begin{matrix}
{T\left( { A,B} \right) = \frac{A \cdot B}{\left\| A \right\|^{2} + \left\| B \right\|^{2} - A \cdot B},} \\
\end{matrix}$$where *A* is the molecular descriptors of herbal compounds, *B* represents the average molecular properties of all compounds in DrugBank database (<http://www.drugbank.ca/>) \[[@B23]\]. The DL ≥ 0.18 (average value for DrugBank) was defined as the criterion to select those drug-like compounds which are chemically suitable for drugs.

### 2.1.3. Caco-2 Permeability Prediction {#sec2.1.3}

The majority of orally administered drugs absorption occurs in the small intestine where the surface absorptivity greatly improves with the presence of villi and microvilli \[[@B24]\]. Previously, researchers have developed a quantity of*in silico* drug absorption models using*in vitro* Caco-2 permeability in drug discovery and development processes \[[@B25]\]. In this study, based on 100 drug molecules with satisfactory statistical results, a robust*in silico* Caco-2 permeability prediction model pre-Caco-2 (predicts Caco-2 permeability) was employed to predict the compound\'s intestinal absorption \[[@B26]\]. Finally, on the account of the fact that compounds with Caco-2 value less than 0 are not permeable, in the study, the threshold of Caco-2 permeability was set to 0.

### 2.1.4. Drug HL Prediction {#sec2.1.4}

An*in silico* pre-HL (predicts half-life) has been developed in our previous work to calculate the drug HL by using the C-partial least square (C-PLS) algorithm which is supported by 169 drugs with known half-life values \[[@B27]--[@B29]\]. HL evaluates the time needed for compounds in the body to fall by half, and components with long HL were selected as the candidate molecules.

In order to obtain the potential active ingredients, the screening principle was defined as follows: OB ≥ 30%; Caco-2 ≥ 0; DL ≥ 0.18; or long HL.

2.2. Drug Targeting {#sec2.2}
-------------------

Apart from screening out the active compounds, the therapeutic targets exploration is also a vital stage. Firstly, the potential targets exploration was fulfilled based on the systematic drug targeting tool (SysDT) as described in our previous work. Based on two mathematical tools, Random Forest (RF) and Support Vector Machine (SVM), the method can comprehensively ascertain the compound-target interaction profiles \[[@B30]\]. These two models exert great property of predicting the drug-target mutual effects with a concordance of 82.83%, a sensitivity of 81.33%, and a specificity of 93.62%. In this work, the compound-target interactions with SVM score ≥ 0.8 and the RF score ≥ 0.7 were selected for further research. Secondly, a recently developed computational model named weighted ensemble similarity (WES) was also introduced to detect drug direct targets \[[@B31]\]. For internal validation, this model performed remarkably well in predicting the binding (average sensitivity 72%, SEN) and the nonbinding (average specificity 82%, SPE) patterns, with the average areas under the receiver operating curves (ROC, AUC) of 85.2% and an average concordance of 77.5%. Thirdly, the obtained protein targets were mapped to the database UniProt (<http://www.uniprot.org/>) for normalization \[[@B32]\]. Finally, in order to identify and analyze the specific biological properties of the potential targets, the Gene Ontology (GO) biological processes were introduced to dissect target genes in a hierarchically structured way based on biological terms \[[@B33]\]. The GlueGO, a Cytoscape plug-in, was utilized to interpret the biology processes of large lists of genes.

2.3. Network Construction and Analysis {#sec2.3}
--------------------------------------

In order to explore the multiple mechanisms of action of XJDH for VHF, currently we analyzed the relationship between candidate compounds and potential targets by constructing the drug-target network (D-T network), in which all active compounds are connected to their targets. The network was generated by Cytoscape 2.8.1 \[[@B34]\]. In the network, compounds and targets are represented by nodes, while the interactions between them are represented by edges. In addition, a vital topological parameter, namely, degree was analyzed by the plugin NetworkAnalyzer of Cytoscape \[[@B35]\]. The degree of a node is defined as the number of edges connected to the node.

2.4. Pathway Construction and Analysis {#sec2.4}
--------------------------------------

At the pathway level, in order to probe into the action mechanisms of the formula for VHF, an incorporated "VHF pathway" was established based on the current knowledge of VHF pathology. Firstly, the obtained human target proteins were collected to be input into the Kyoto Encyclopedia of Genes and Genomes (KEGG, <http://www.kegg.jp/>) database to acquire the information of pathways. Then, based on the obtained information of basic pathways, we assembled an incorporated "VHF pathway" by picking out closely linked pathways related with VHF pathology.

3. Results {#sec3}
==========

3.1. Active Compounds Screening {#sec3.1}
-------------------------------

We employed four ADME parameters to screen out the potential active components of XJDH. As a result, from the 136 compounds of XJDH (as shown in supporting information, Table S1, in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/9025036>), a total of 20 active compounds pass through the criteria of OB ≥ 30%, Caco-2 ≥ 0, DL ≥ 0.18, or long HL. Besides, in order to obtain a more accurate result, some certain rejected compounds, which have relatively poor pharmacokinetic properties, but are the most abundant and active ingredients of certain herbs, were also selected as the active components for further research. For example, although catalpol (MOL108) has poor OB, Caco-2, and HL properties, it has been reported to be rich in the roots of*Rehmannia dried* rhizome. And rehmaglutin D (MOL116) and paeoniflorin (MOL046) with poor OB (14.43%) take a large proportion in*Paeonia lactiflora* Pall. Thus, the three compounds were also retained for further analysis. Finally, a total of 23 active ingredients were obtained in this study (as shown in [Table 1](#tab1){ref-type="table"}).

For all these 23 ingredients, many of them have been reported to demonstrate significant biologic activity including anti-inflammatory, antivirus, antipyretic, and immune-regulatory activities and protection effect of vascular endothelial cell. For instance, methyl gallate (MOL006, OB = 30.91%, Caco-2 = 0.26, and long HL), obtained from*Paeonia lactiflora* Pall., shows antivirus activity by interacting with virus proteins and altering the adsorption and penetration of the virion \[[@B36]\]. Salicylic acid (MOL045, OB = 32.13%, Caco-2 = 0.63, and long HL) and paeoniflorin (MOL046) with poor OB from*Paeonia lactiflora* Pall. exhibit antipyretic, anti-inflammatory, and immune-regulatory activities \[[@B37], [@B38]\]. In addition, kaempferol (MOL060, OB = 69.61%, Caco-2 = 0.15, DL = 0.24, and long HL), paeonol (MOL072, OB = 30.98%, Caco-2 = 0.91, long HL), and eugenol (MOL070, OB = 44.47%, Caco-2 = 1.36, and long HL), the main active compounds of the radix of*Paeonia suffruticosa* Andr., have been reported to have potential therapeutic effect for inflammation and vascular injury disorders \[[@B39]--[@B41]\]. Besides, it is worth noting that *β*-sitosterol (MOL018, OB = 36.9%, DL = 0.75) is a common ingredient of*Rehmannia dried* rhizome,*Paeonia lactiflora* Pall., and*Paeonia suffruticosa* Andr., indicating that these active compounds may show synergetic pharmacological effects on VHF.

3.2. Drug Targeting and Functional Analysis {#sec3.2}
-------------------------------------------

Traditional information retrieval approaches of therapeutic targets of drugs are expatiatory and complicated \[[@B42]\]. To overcome this barrier, we introduced our previous developed target prediction model \[[@B30], [@B31]\] to dissect interactions between drugs and proteins. As a result, 23 candidate compounds are linked with 118 candidate targets (as shown in [Table 2](#tab2){ref-type="table"}). The results show that many components simultaneously can act on more than one target and many targets can connect to all of the four medicines, demonstrating the promiscuous actions and analogous pharmacological effects of the bioactive molecules. For instance, kaempferol (MOL060) not only serves as the restrainer of Prostaglandin G/H synthase 2 \[[@B44]\] but also acts as the inhibitor of tumor necrosis factor \[[@B45]\]. And *β*-sitosterol (MOL018), which is shared by*Rehmannia dried* rhizome,*Paeonia lactiflora* Pall., and*Paeonia suffruticosa* Andr., acts as the activator of estrogen receptor \[[@B46]\] and transcription factor AP-1 \[[@B47]\]. Meanwhile, the results show that different drugs in XJDH can immediately impact on the common targets such as DNA ligase 1 (LIG1), indicating the synergism or cumulative effects of the drug molecules.

In general, vascular system, particularly the endothelium, plays a key role in VHF development \[[@B3]\]. A strong inflammatory response characterized by high circulating concentrations of cytokines and chemokines occurs early during the VHF infectious process \[[@B48]\]. And the patients\' immune functions might also be severely impaired; innate defenses are further hindered by the loss of natural killer cells \[[@B49]\]. The relevant biological processes of above targets were revealed by GlueGO (as shown in supporting information, Table S2). [Figure 2](#fig2){ref-type="fig"} provides primary biological processes of these targets by cluster analysis. It is interesting to note that these targets are involved in a variety of biological processes including regulation of macrophage derived from cell differentiation, regulation of vasoconstriction and vasodilation, nitric oxide biosynthetic process, and vascular process in circulatory system. These biological processes largely fall into three groups: controlling inflammation response, modulating the immune system, and accommodation of vascular system. For example, peroxisome proliferator-activated receptor gamma (PPAR*γ*), tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), beta-2 adrenergic receptor (ADRB2), and so forth are involved in the regulation of acute inflammatory response. Nitric oxide synthase, inducible (NOS2), dipeptidyl peptidase 4 (DPP4), and so forth are associated with regulation of immune effector process, while nitric oxide synthase, endothelial (NOS3), NOS2, Krüppel-like factor 5 (KLF5), and so forth are directly connected to blood vessel remodeling and blood vessel morphogenesis. These suggest that XJDH might exert the therapeutic effect on VHF mainly through anti-inflammation, enhancing immunity and vascular repair therapy.

3.3. Drug-Target Network Construction and Analysis {#sec3.3}
--------------------------------------------------

As shown in [Figure 3](#fig3){ref-type="fig"}, D-T network is constructed including 141 nodes (23 active compounds and 118 potential targets) and 382 edges. The degrees of the candidate compounds are shown in [Table 1](#tab1){ref-type="table"}; this provides us with an intuitionistic concept to distinguish those highly connected vital compounds or targets from the others in the network. The results of network analysis show that 18 out of 23 candidate compounds are linked with more than ten targets, among which kaempferol (MOL060) displays the highest number of target interactions (degree = 41), followed by eugenol (MOL070, degree = 34) and paeonol (MOL072, degree = 27). This confirms the multitarget properties of herbal compounds. We speculate that the top three ingredients might be the crucial elements in the treatment of VHF. For instance, kaempferol (MOL060) is predicted to interact with 41 targets like calcitonin gene-related peptide type 1 receptor (MAPK14), PPAR*γ*, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG). MAPK14 takes part in the vascular endothelial growth factor (VEGF) synthesis through the mediation of angiotensin II \[[@B50]\]. VEGF can induce angiogenesis and improve the increased vascular permeability, so as to prevent bleeding in patients with VHF \[[@B51]\]. Besides, kaempferol is also found to significantly upregulate the transcriptional activity of PPAR*γ*, which acts as an inhibitor of inflammatory gene expression and vandalizes proinflammatory transcription factor signaling pathways in vascular cells \[[@B52]\]. Additionally, previous finding suggests that PIK3CG interacting with kaempferol can participate in inflammation processes and influence the innate immune system \[[@B53]\]. Thus, these key active ingredients of XJDH work mainly by modulating inflammatory factor, innate immune system, and VEGF.

Meanwhile, the results also show that one target can be hit by multiple compounds from different medicines, indicating synergism or summation effects of the formula. According to the D-T network analysis, 64 out of the 118 targets have at least two links with the components of different herbs. XJDH exerts its therapeutic effect for VHF by binding and regulating particular protein targets. For instance, prostaglandin G/H synthase 2 (PTGS2) is simultaneously targeted by 10 active compounds including eugenol (MOL070, from*Paeonia suffruticosa* Andr.), paeonol (MOL072, from*Paeonia suffruticosa* Andr.), and salicylic acid (MOL045, from*Paeonia lactiflora* Pall.). PTGS2 is possibly an effective marker of platelet dysfunction; a reduced PTGS2 expression in the VHF primate model cells could directly result in platelet dysfunction \[[@B54]\]. Fortunately, in agreement with our study, previous findings suggest that eugenol and paeonol can control the expression of PTGS2 through the suppression of NF-*κ*B in macrophage \[[@B55]--[@B57]\], so as to recover the function of thrombocyte. Study shows that severe disseminated intravascular coagulation is the mechanisms of bleeding in all VHF \[[@B3]\]. Prothrombin (F2), the precursor substances of clotting enzyme, plays a crucial role in optimizing the procoagulant activity through controlling the anticoagulant function of meizothrombin \[[@B58]\]. Thus, these 10 ingredients such as methyl gallate (MOL006, from*Paeonia lactiflora* Pall.), salicylic acid (MOL045, from*Paeonia lactiflora* Pall.), and apocynin (MOL053,*Paeonia suffruticosa* Andr.) interacting with F2 may be the key factors in the treatment of bleeding in patients with VHF. By analyzing the above D-T network, we can conclude that XJDH produces the healing efficacy for VHF probably by three different ways, intervening in the process of inflammation, boosting immune reaction, and repairing vascular system.

3.4. Pathway Analysis {#sec3.4}
---------------------

To explore the integral regulation of XJDH for the treatment of VHF, we assembled an integrated "VHF pathway" ([Figure 4](#fig4){ref-type="fig"}) on the basis of the current knowledge of VHF pathogenesis. By means of inputting the obtained human target proteins into KEGG pathway database, result shows that 110 of the 118 targets can be mapped to the KEGG pathways, including NF-*κ*B signaling pathway, AMPK pathway, and PI3K-AKT signaling pathway. Now, three detailed therapeutic modules are provided (inflammation module, angiogenesis module, and virus spreading module).

### 3.4.1. Inflammation Module {#sec3.4.1}

As shown in [Figure 4](#fig4){ref-type="fig"}, 7 key proteins targeted by XJDH are mapped onto a key inflammation process, namely, NF-*κ*B signaling pathway, indicating the anti-inflammatory action may play a vital role in the treatment of VHF. Patients with VHF have a strong inflammatory response with high inflammatory cytokines and chemokines levels such as IL-1*β*, TNF, and IL-6 in the early phase of VHF \[[@B48]\]. The expression of inflammatory cytokines (TNF-*α*, IL-1*β*, IL-6, and IL-8) is mediated by NF-*κ*B \[[@B59]\], and NF-*κ*B is one of the most important regulators of proinflammatory gene expression. The result demonstrates that paeoniflorin (MOL046) from*Paeonia lactiflora* Pall. and*Paeonia suffruticosa* Andr. can regulate transcription factor NF-*κ*B activity. Meanwhile, other researchers have verified that paeoniflorin can restrain the activation of the NF-*κ*B pathway via inhibiting I*κ*B kinase \[[@B60]\]. In addition, vascular adhesion molecule 1 (VCAM-1), a cell adhesion molecule, also plays an important role in the pathogenesis of inflammatory and immune processes \[[@B61]\]. Our work indicates that kaempferol (MOL060) and *β*-sitosterol (MOL018) can regulate the expression of inflammatory cytokines by targeting vascular adhesion molecule 1 (VCAM-1). Consequently, the foregoing analysis shows that XJDH has the effect of ameliorating the symptoms of inflammation disorders of patients with VHF.

### 3.4.2. Virus Spreading Module {#sec3.4.2}

In [Figure 4](#fig4){ref-type="fig"}, the phosphoinositide-3 kinase (PI3K) pathway is a significant cell signaling pathway that regulates diverse cellular activities including cell proliferation, differentiation, apoptosis, and vesicular trafficking. Notably, our research shows that, in line with previous studies, kaempferol (MOL060) is predicted to modulate PI3Ks activity, and AKT is also a target for kaempferol (MOL060) and paeonol (MOL072) \[[@B62]--[@B64]\]. Besides, PI3Ks, a family of lipid kinases, can prevent hemorrhagic fever virus entry into host cells by regulating cellular activities of vesicular trafficking \[[@B65]\]. AKT is a major downstream effector of the PI3K pathway, and this target protein can control the expression of many molecules directly or indirectly. Moreover, evidence also suggests that activity of PI3K/Akt pathway is required for hemorrhagic fever virus intruding into the host cells \[[@B65]\]. Therefore, depressors of PI3K and AKT dramatically reduced the risk of hemorrhagic fever virus infection at an early step during the replication cycle. These above analyses show that XJDH could make effective control of hemorrhagic fever virus entry into cells, thus blocking virus spread by interfering with the PI3K-AKT signaling pathway.

### 3.4.3. Angiogenesis Module {#sec3.4.3}

VHF is a severe multisystem syndrome characterized by diffuse vascular damage. The vascular system, particularly the vascular endothelium, seems to be directly and indirectly targeted by hemorrhagic fever viruses \[[@B3]\]. In the VHF pathway shown in [Figure 4](#fig4){ref-type="fig"}, PI3K pathway and AMPK pathway are involved in regulating the angiogenesis progress. We find out that apocynin (MOL053), kaempferol (MOL060), methyl salicylate (MOL066), and eugenol (MOL070) can affect the activity of endothelial NO synthase (eNOS) and then bring about NO production changes in endothelial cell. Moreover, at present, a large number of researches indicate that the synthesis of bioactive endothelium-derived NO is required for the progress of angiogenesis \[[@B66]--[@B68]\]. Therefore, the evidence presented enables us to reasonably conclude that the XJDH takes part in regulation of angiogenesis progress through PI3K signaling pathway and AMPK pathway.

4. Discussion {#sec4}
=============

Actually, XJDH has been normally used for cooling the blood for hemostasis, stopping bleeding accompanied with fever, removing toxic substances, and treating the cases of high fever and sweating, spontaneous bleeding, hemoptysis, and nosebleeds \[[@B13], [@B69]\]. Although XJDH has been used historically for treating hemorrhagic fever syndromes, the specific bioactive molecules responsible for VHF and their precise mechanisms of action are still unclear. Thus, in this work, a systems pharmacology method combining the screening active components, drug targeting, network, and pathway analysis was carried out, so as to uncover the active ingredients, targets, and pathways of XJDH and systematically decipher its therapeutic mechanism of actions.

Our results show that 23 active ingredients were obtained from XJDH, and 118 potential targets were predicted. These manifest that the characteristics of XJDH are multicomponent botanical therapeutics and multitargets synergetic therapeutic effects. The GO analysis of targets and integrated D-T network analysis demonstrate the synergistic effects of XJDH for the treatment of VHF mainly through boosting of immune system, inhibiting inflammatory response, and repairing vascular system. Meanwhile, the integrated "VHF pathway" analysis in our work shows that XJDH might simultaneously regulate multitargets/pathways coupled with a range of therapeutic modules, for example, anti-inflammation, antivirus, and angiogenesis.

Now most researchers believe that VHF can be attributed to the simultaneous occurrence of multiple pathogenic mechanisms. They are mainly as follows: hemorrhagic fever virus infection stimulates macrophages to release cytokines, chemokines, and other mediators, causing fever, malaise, alterations in vascular function, and a shift in the coagulation system toward a procoagulant state, and immune functions might also be severely impaired \[[@B2]\]. Besides, hemorrhagic fever virus can target the vascular system directly and indirectly and cause endothelial activation and dysfunction \[[@B3]\]. In this study, we show here for the first time using GO enrichment analysis, network analysis, and integrated pathway analysis that XJDH significantly enriches target genes involved in reducing the inflammation response, enhancing immunity, combating the spreading virus, and preventing vascular dysfunction. And more experiments are needed to verify the validity of the results in further research works.

5. Conclusions {#sec5}
==============

The result of this study provides bioactive ingredients, vital targets, and pathways of XJDH. We have come to the conclusion that the action mechanisms of XJDH for VHF mainly include restoring the immune system and enhancing immune response, ameliorating the symptoms of inflammation disorders, improving their vascular endothelial dysfunction, and combating the spreading virus. The systems pharmacology method established in our work provides preliminary clues that the multilayer networks of drug-target paradigm may be valuable for the modernization of TCM formulas at molecular level and then push forward their acceptance into mainstream medicine.
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![The detailed flowchart of the systems pharmacology method.](ECAM2016-9025036.001){#fig1}

![ClueGO analysis of the potential targets. *y*-axis shows significantly enriched "biological process" (BP) categories in GO relative to the target genes, and *x*-axis shows the counts of targets.](ECAM2016-9025036.002){#fig2}

![D-T network. The blue circles represent candidate compounds in XJDH, while the green circles represent target proteins, and each edge represents the interaction between them.](ECAM2016-9025036.003){#fig3}
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###### 

23 potential compounds of XJDH and their network parameters.

  MOL_ID   Compounds                                                       Structure                             OB      Caco-2   DL      HL      Degree   Medicines
  -------- --------------------------------------------------------------- ------------------------------------- ------- -------- ------- ------- -------- -----------------------------------------------------------------------------------
  MOL001   Cholesterol                                                     ![](ECAM2016-9025036.tab1.i001.jpg)   37.87   1.31     0.68    Long    16       *Buffalo Horn*
                                                                                                                                                           
  MOL004   2,2-Dimethylcyclohexanol                                        ![](ECAM2016-9025036.tab1.i002.jpg)   82.54   1.22     0.02    Long    12       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL005   Dibutylphenol                                                   ![](ECAM2016-9025036.tab1.i003.jpg)   38.90   1.73     0.06    Long    15       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL006   Methyl gallate                                                  ![](ECAM2016-9025036.tab1.i004.jpg)   30.91   0.26     0.05    Long    17       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL014   (−)-Alpha-cedrene                                               ![](ECAM2016-9025036.tab1.i005.jpg)   55.56   1.81     0.10    Long    16       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL018   *β*-Sitosterol                                                  ![](ECAM2016-9025036.tab1.i006.jpg)   36.91   1.34     0.75    Short   21       *Paeonia lactiflora* Pall.,*Paeonia suffruticosa* Andr.,*Rehmannia dried* rhizome
                                                                                                                                                           
  MOL025   Dipropyl Phthalate                                              ![](ECAM2016-9025036.tab1.i007.jpg)   66.30   0.78     0.10    Long    8        *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL031   Mairin                                                          ![](ECAM2016-9025036.tab1.i008.jpg)   55.38   0.73     0.78    Short   14       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL041   Acetyl oxide                                                    ![](ECAM2016-9025036.tab1.i009.jpg)   45.13   0.65     0       Long    12       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL045   Salicylic acid                                                  ![](ECAM2016-9025036.tab1.i010.jpg)   32.13   0.63     0.027   Long    19       *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL046   Paeoniflorin                                                    ![](ECAM2016-9025036.tab1.i011.jpg)   14.43   −1.38    0.79    Short   5        *Paeonia lactiflora* Pall.
                                                                                                                                                           
  MOL053   Apocynin                                                        ![](ECAM2016-9025036.tab1.i012.jpg)   31.71   0.74     0.04    Long    22       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL060   Kaempferol                                                      ![](ECAM2016-9025036.tab1.i013.jpg)   69.61   0.15     0.24    Long    41       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL066   Methyl salicylate                                               ![](ECAM2016-9025036.tab1.i014.jpg)   42.55   1.05     0.03    Long    17       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL070   Eugenol                                                         ![](ECAM2016-9025036.tab1.i015.jpg)   44.47   1.36     0.04    Long    34       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL072   Paeonol                                                         ![](ECAM2016-9025036.tab1.i016.jpg)   30.98   0.91     0.04    Long    27       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL073   5-\[\[5-(4-Methoxyphenyl)-2-furyl\]methylene\]barbituric acid   ![](ECAM2016-9025036.tab1.i017.jpg)   43.44   0.09     0.30    Long    10       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL075   1-(2,3-Dihydroxy-4-methoxyphenyl)ethanone                       ![](ECAM2016-9025036.tab1.i018.jpg)   32.96   0.81     0.05    Long    25       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL077   Vanillic acid                                                   ![](ECAM2016-9025036.tab1.i019.jpg)   35.47   0.43     0.04    Long    13       *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL078   (1R)-(+)-Nopinone                                               ![](ECAM2016-9025036.tab1.i020.jpg)   57.86   1.23     0.05    Long    7        *Paeonia suffruticosa* Andr.
                                                                                                                                                           
  MOL096   Stigmasterol                                                    ![](ECAM2016-9025036.tab1.i021.jpg)   43.83   1.44     0.76    Short   18       *Rehmannia dried* rhizome
                                                                                                                                                           
  MOL108   Catalpol                                                        ![](ECAM2016-9025036.tab1.i022.jpg)   14.78   −2.10    0.44    Short   6        *Rehmannia dried* rhizome
                                                                                                                                                           
  MOL116   Rehmaglutin D                                                   ![](ECAM2016-9025036.tab1.i023.jpg)   62.9    −0.31    0.1     Long    7        *Rehmannia dried* rhizome

###### 

The VHF-related targets information.

  UniProt ID   Name                                                                             Gene name   Species
  ------------ -------------------------------------------------------------------------------- ----------- ----------------
  O14920       Inhibitor of nuclear factor kappa-B kinase subunit beta                          IKBKB       *Homo sapiens*
  P19320       Vascular cell adhesion protein 1                                                 VCAM1       *Homo sapiens*
  P31749       RAC-alpha serine/threonine-protein kinase                                        AKT1        *Homo sapiens*
  P19838       Nuclear factor NF-kappa-B p105 subunit                                           NFKB1       *Homo sapiens*
  P25963       NF-kappa-B inhibitor alpha                                                       NFKBIA      *Homo sapiens*
  A1L156       LTB4R2 protein                                                                   LTB4R2      *Homo sapiens*
  F1D8P7       Liver X nuclear receptor beta                                                    NR1H2       *Homo sapiens*
  O00748       Cocaine esterase                                                                 CES2        *Homo sapiens*
  O14757       Serine/threonine-protein kinase Chk1                                             CHEK1       *Homo sapiens*
  O15528       25-Hydroxyvitamin D-1 alpha hydroxylase, mitochondrial                           CYP27B1     *Homo sapiens*
  O43570       Carbonic anhydrase 12                                                            CA12        *Homo sapiens*
  O60218       Aldo-keto reductase family 1 member B10                                          AKR1B10     *Homo sapiens*
  O95622       Adenylate cyclase type 5                                                         ADCY5       *Homo sapiens*
  P00325       Alcohol dehydrogenase 1B                                                         ADH1B       *Homo sapiens*
  P00734       Prothrombin                                                                      F2          *Homo sapiens*
  P00797       Renin                                                                            REN         *Homo sapiens*
  P00915       Carbonic anhydrase 1                                                             CA1         *Homo sapiens*
  P00918       Carbonic anhydrase 2                                                             CA2         *Homo sapiens*
  P03372       Estrogen receptor                                                                ESR1        *Homo sapiens*
  P04150       Glucocorticoid receptor                                                          NR3C1       *Homo sapiens*
  P04798       Cytochrome P450 1A1                                                              CYP1A1      *Homo sapiens*
  P05067       Amyloid beta A4 protein                                                          APP         *Homo sapiens*
  P05091       Aldehyde dehydrogenase, mitochondrial                                            ALDH2       *Homo sapiens*
  P05093       Steroid 17-alpha-hydroxylase/17,20 lyase                                         CYP17A1     *Homo sapiens*
  P05177       Cytochrome P450 1A2                                                              CYP1A2      *Homo sapiens*
  P06276       Cholinesterase                                                                   BCHE        *Homo sapiens*
  P06746       DNA polymerase beta                                                              POLB        *Homo sapiens*
  P07550       Beta-2 adrenergic receptor                                                       ADRB2       *Homo sapiens*
  P07686       Beta-hexosaminidase subunit beta                                                 HEXB        *Homo sapiens*
  P07900       Heat shock protein HSP 90-alpha                                                  HSP90AA1    *Homo sapiens*
  P08172       Muscarinic acetylcholine receptor M2                                             CHRM2       *Homo sapiens*
  P08183       Multidrug resistance protein 1                                                   ABCB1       *Homo sapiens*
  P08235       Mineralocorticoid receptor                                                       NR3C2       *Homo sapiens*
  P08588       Beta-1 adrenergic receptor                                                       ADRB1       *Homo sapiens*
  P08913       Alpha-2A adrenergic receptor                                                     ADRA2A      *Homo sapiens*
  P09917       Arachidonate 5-lipoxygenase                                                      ALOX5       *Homo sapiens*
  P10253       Lysosomal alpha-glucosidase                                                      GAA         *Homo sapiens*
  P10275       Androgen receptor                                                                AR          *Homo sapiens*
  P10636       Microtubule-associated protein tau                                               MAPT        *Homo sapiens*
  P11229       Muscarinic acetylcholine receptor M1                                             CHRM1       *Homo sapiens*
  P11309       Serine/threonine-protein kinase pim-1                                            PIM1        *Homo sapiens*
  P11413       Glucose-6-phosphate 1-dehydrogenase                                              G6PD        *Homo sapiens*
  P11413       Glucose-6-phosphate 1-dehydrogenase                                              G6PD        *Homo sapiens*
  P11473       Vitamin D3 receptor                                                              VDR         *Homo sapiens*
  P11509       Cytochrome P450 2A6                                                              CYP2A6      *Homo sapiens*
  P11712       Cytochrome P450 2C9                                                              CYP2C9      *Homo sapiens*
  P12931       Proto-oncogene tyrosine-protein kinase Src                                       SRC         *Homo sapiens*
  P14222       Perforin-1                                                                       PRF1        *Homo sapiens*
  P14867       Gamma-aminobutyric-acid receptor subunit alpha-1                                 GABRA1      *Homo sapiens*
  P15121       Aldose reductase                                                                 AKR1B1      *Homo sapiens*
  P16152       Carbonyl reductase \[NADPH\] 1                                                   CBR1        *Homo sapiens*
  P16278       Beta-galactosidase                                                               GLB1        *Homo sapiens*
  P16662       UDP-glucuronosyltransferase 2B7                                                  UGT2B7      *Homo sapiens*
  P17538       Chymotrypsinogen B                                                               CTRB1       *Homo sapiens*
  P18031       Tyrosine-protein phosphatase nonreceptor type 1                                  PTPN1       *Homo sapiens*
  P18089       Alpha-2B adrenergic receptor                                                     ADRA2B      *Homo sapiens*
  P18825       Alpha-2C adrenergic receptor                                                     ADRA2C      *Homo sapiens*
  P18858       DNA ligase 1                                                                     LIG1        *Homo sapiens*
  P19438       Tumor necrosis factor receptor superfamily member 1A                             TNFRSF1A    *Homo sapiens*
  P19801       Amiloride-sensitive amine oxidase \[copper-containing\]                          AOC1        *Homo sapiens*
  P20248       Cyclin-A2                                                                        CCNA2       *Homo sapiens*
  P20309       Muscarinic acetylcholine receptor M3                                             CHRM3       *Homo sapiens*
  P21397       Amine oxidase \[flavin-containing\] A                                            MAOA        *Homo sapiens*
  P21728       D(1A) dopamine receptor                                                          DRD1        *Homo sapiens*
  P22303       Acetylcholinesterase                                                             ACHE        *Homo sapiens*
  P23219       Prostaglandin G/H synthase 1                                                     PTGS1       *Homo sapiens*
  P23368       NAD-dependent malic enzyme, mitochondrial                                        ME2         *Homo sapiens*
  P23945       Follicle-stimulating hormone receptor                                            FSHR        *Homo sapiens*
  P23975       Sodium-dependent noradrenaline transporter                                       SLC6A2      *Homo sapiens*
  P24941       Cell division protein kinase 2                                                   CDK2        *Homo sapiens*
  P25100       Alpha-1D adrenergic receptor                                                     ADRA1D      *Homo sapiens*
  P27338       Amine oxidase \[flavin-containing\] B                                            MAOB        *Homo sapiens*
  P27487       Dipeptidyl peptidase 4                                                           DPP4        *Homo sapiens*
  P28223       5-Hydroxytryptamine 2A receptor                                                  HTR2A       *Homo sapiens*
  P29474       Nitric oxide synthase, endothelial                                               NOS3        *Homo sapiens*
  P29475       Nitric oxide synthase, brain                                                     NOS1        *Homo sapiens*
  P31350       Ribonucleoside-diphosphate reductase subunit M2                                  RRM2        *Homo sapiens*
  P33527       Multidrug resistance-associated protein 1                                        ABCC1       *Homo sapiens*
  P35228       Nitric oxide synthase, inducible                                                 NOS2        *Homo sapiens*
  P35348       Alpha-1A adrenergic receptor                                                     ADRA1A      *Homo sapiens*
  P35354       Prostaglandin G/H synthase 2                                                     PTGS2       *Homo sapiens*
  P35869       Aryl hydrocarbon receptor                                                        AHR         *Homo sapiens*
  P36888       Receptor-type tyrosine-protein kinase FLT3                                       FLT3        *Homo sapiens*
  P37231       Peroxisome proliferator-activated receptor gamma                                 PPARG       *Homo sapiens*
  P43681       Neuronal acetylcholine receptor subunit alpha-4                                  CHRNA4      *Homo sapiens*
  P47989       Xanthine dehydrogenase/oxidase \[includes xanthine dehydrogenase\]               XDH         *Homo sapiens*
  P48736       Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform   PIK3CG      *Homo sapiens*
  P49841       Glycogen synthase kinase-3 beta                                                  GSK3B       *Homo sapiens*
  P51684       C-C chemokine receptor type 6                                                    CCR6        *Homo sapiens*
  P51843       Nuclear receptor subfamily 0 group B member 1                                    NR0B1       *Homo sapiens*
  P53634       Dipeptidyl peptidase 1                                                           CTSC        *Homo sapiens*
  P60174       Triose-phosphate isomerase                                                       TPI1        *Homo sapiens*
  P80365       Corticosteroid 11-beta-dehydrogenase isozyme 2                                   HSD11B2     *Homo sapiens*
  P80404       4-Aminobutyrate aminotransferase, mitochondrial                                  ABAT        *Homo sapiens*
  P84022       Mothers against decapentaplegic homolog 3                                        SMAD3       *Homo sapiens*
  Q00534       Cyclin-dependent kinase 6                                                        CDK6        *Homo sapiens*
  Q04760       Lactoylglutathione lyase                                                         GLO1        *Homo sapiens*
  Q07075       Glutamyl aminopeptidase                                                          ENPEP       *Homo sapiens*
  Q07973       1,25-Dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial                         CYP24A1     *Homo sapiens*
  Q12791       Calcium-activated potassium channel subunit alpha-1                              KCNMA1      *Homo sapiens*
  Q12882       Dihydropyrimidine dehydrogenase \[NADP(+)\]                                      DPYD        *Homo sapiens*
  Q13822       Ectonucleotide pyrophosphatase/phosphodiesterase family member 2                 ENPP2       *Homo sapiens*
  Q13887       Krüppel-like factor 5                                                            KLF5        *Homo sapiens*
  Q14524       Sodium channel protein type 5 subunit alpha                                      SCN5A       *Homo sapiens*
  Q14973       Sodium/bile acid cotransporter                                                   SLC10A1     *Homo sapiens*
  Q16539       Mitogen-activated protein kinase 14                                              MAPK14      *Homo sapiens*
  Q16602       Calcitonin gene-related peptide type 1 receptor                                  CALCRL      *Homo sapiens*
  Q16678       Cytochrome P450 1B1                                                              CYP1B1      *Homo sapiens*
  Q16853       Membrane primary amine oxidase                                                   AOC3        *Homo sapiens*
  Q92731       Estrogen receptor beta                                                           ESR2        *Homo sapiens*
  Q96IY4       Carboxypeptidase B2                                                              CPB2        *Homo sapiens*
  Q9H5J4       Elongation of very long chain fatty acids protein 6                              ELOVL6      *Homo sapiens*
  Q9HBH1       Peptide deformylase, mitochondrial                                               PDF         *Homo sapiens*
  Q9NPH5       NADPH oxidase 4                                                                  NOX4        *Homo sapiens*
  Q9NYA1       Sphingosine kinase 1                                                             SPHK1       *Homo sapiens*
  Q9UBM7       7-Dehydrocholesterol reductase                                                   DHCR7       *Homo sapiens*
  Q9UNQ0       ATP-binding cassette subfamily G member 2                                        ABCG2       *Homo sapiens*
  Q9Y263       Phospholipase A-2-activating protein                                             PLAA        *Homo sapiens*
  Q9Y2I1       Nischarin                                                                        NISCH       *Homo sapiens*

[^1]: Academic Editor: Hyunsu Bae
